Ignite Creation Date:
2025-12-25 @ 2:59 AM
Ignite Modification Date:
2026-01-08 @ 2:39 AM
Study NCT ID:
NCT03082833
Status:
TERMINATED
Last Update Posted:
2019-05-20
First Post:
2017-02-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy
Sponsor:
Samsung Medical Center
Organization:
Study Overview
Official Title:
Samsung Medical Center
Status:
TERMINATED
Status Verified Date:
2019-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
lack of efficacy
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase II trial of AZD2014 in TSC1/2 mutated or TSC1/2 null GC patients as second-line chemotherapy
Detailed Description:
AZD2014 50mg BD continuous schedule of a 28 day cycle AZD2014 will be administered with orange juice in STG/TG patients. AZD2014 can be taken with or without food. The first dose of the day should be taken at approximately the same time each morning.The second dose of the day should be taken approximately 12 hours after the morning dose.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: